iSpecimen annual stock-based compensation
2020
2021
2022
2023
2024
2025
iSpecimen Stock-Based Compensation Growth & History (ISPC)
iSpecimen's stock-based compensation was $21,266 for fiscal 2025.
View full iSpecimen company overviewiSpecimen annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $21,266 | −$228,409 | −91.48% |
| 2024 | 2024-12-31 | $249,675 | −$209,991 | −45.68% |
| 2023 | 2023-12-31 | $459,666 | −$218,947 | −32.26% |
| 2022 | 2022-12-31 | $678,613 | $56,549 | +9.09% |
| 2021 | 2021-12-31 | $622,064 | $529,198 | +569.85% |
| 2020 | 2020-12-31 | $92,866 | — | — |
iSpecimen quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $153 | −$1,650 | −91.51% |
| Q1 2026 | 2026-03-31 | $1,028 | −$14,873 | −93.53% |
| Q4 2025 | 2025-12-31 | $1,765 | −$9,207 | −83.91% |
| Q3 2025 | 2025-09-30 | $1,797 | −$63,344 | −97.24% |
| Q2 2025 | 2025-06-30 | $1,803 | −$77,834 | −97.74% |
| Q1 2025 | 2025-03-31 | $15,901 | −$78,024 | −83.07% |
| Q4 2024 | 2024-12-31 | $10,972 | −$97,147 | −89.85% |
| Q3 2024 | 2024-09-30 | $65,141 | −$41,152 | −38.72% |
| Q2 2024 | 2024-06-30 | $79,637 | −$45,060 | −36.14% |
| Q1 2024 | 2024-03-31 | $93,925 | −$26,632 | −22.09% |
| Q4 2023 | 2023-12-31 | $108,119 | $62,981 | +139.53% |
| Q3 2023 | 2023-09-30 | $106,293 | −$113,643 | −51.67% |
| Q2 2023 | 2023-06-30 | $124,697 | −$104,651 | −45.63% |
| Q1 2023 | 2023-03-31 | $120,557 | −$63,634 | −34.55% |
| Q4 2022 | 2022-12-31 | $45,138 | −$126,695 | −73.73% |
| Q3 2022 | 2022-09-30 | $219,936 | −$179,885 | −44.99% |
| Q2 2022 | 2022-06-30 | $229,348 | $200,974 | +708.30% |
| Q1 2022 | 2022-03-31 | $184,191 | $162,155 | +735.86% |
| Q4 2021 | 2021-12-31 | $171,833 | — | — |
| Q3 2021 | 2021-09-30 | $399,821 | $370,555 | +1266.16% |
| Q2 2021 | 2021-06-30 | $28,374 | −$913 | −3.12% |
| Q1 2021 | 2021-03-31 | $22,036 | — | — |
| Q3 2020 | 2020-09-30 | $29,266 | — | — |
| Q2 2020 | 2020-06-30 | $29,287 | — | — |
iSpecimen stock-based compensation trends
Over the last five fiscal years, iSpecimen's stock-based compensation decreased from $92,866 to $21,266, a change of −$71,600. The latest reported quarter, Q2 2026, shows $153.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review iSpecimen source filings ↗